JP2019506390A - 合成オピオイドワクチン - Google Patents

合成オピオイドワクチン Download PDF

Info

Publication number
JP2019506390A
JP2019506390A JP2018537799A JP2018537799A JP2019506390A JP 2019506390 A JP2019506390 A JP 2019506390A JP 2018537799 A JP2018537799 A JP 2018537799A JP 2018537799 A JP2018537799 A JP 2018537799A JP 2019506390 A JP2019506390 A JP 2019506390A
Authority
JP
Japan
Prior art keywords
fentanyl
vaccine
drug
hapten
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018537799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506390A5 (enExample
Inventor
ジャンダ，キム・ディー
Original Assignee
ザ スクリプス リサーチ インスティテュート
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート, ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2019506390A publication Critical patent/JP2019506390A/ja
Publication of JP2019506390A5 publication Critical patent/JP2019506390A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018537799A 2016-01-21 2017-01-18 合成オピオイドワクチン Pending JP2019506390A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281262P 2016-01-21 2016-01-21
US62/281,262 2016-01-21
PCT/US2017/013865 WO2017127390A1 (en) 2016-01-21 2017-01-18 Synthetic opioid vaccine

Publications (2)

Publication Number Publication Date
JP2019506390A true JP2019506390A (ja) 2019-03-07
JP2019506390A5 JP2019506390A5 (enExample) 2020-02-27

Family

ID=59362842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018537799A Pending JP2019506390A (ja) 2016-01-21 2017-01-18 合成オピオイドワクチン

Country Status (7)

Country Link
US (1) US11305010B2 (enExample)
EP (1) EP3405475B1 (enExample)
JP (1) JP2019506390A (enExample)
CN (1) CN108884127A (enExample)
BR (1) BR112018014908A2 (enExample)
RU (1) RU2018130106A (enExample)
WO (1) WO2017127390A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660331B2 (en) 2017-11-09 2023-05-30 The Scripps Research Institute Heroin vaccine
WO2020006563A1 (en) * 2018-06-29 2020-01-02 Marquette University Fluorinated compounds as ph-sensitive analgesics
WO2021092446A1 (en) * 2019-11-08 2021-05-14 Regents Of The University Of Minnesota Fentanyl hapten, fentanyl hapten-conjugates, and methods for making and using
US20230100186A1 (en) * 2020-01-13 2023-03-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Fentanyl haptens for the preparation of a fentanyl vaccine
US20230126276A1 (en) * 2020-03-13 2023-04-27 Regents Of The University Of Minnesota Fentanyl haptens, fentanyl hapten conjugates, and methods for making and using
US20240307517A1 (en) * 2021-05-10 2024-09-19 Cornell University Development of a highly efficient second generation fentanyl-conjugate vaccine to treat fentanyl addiction
WO2024215826A2 (en) * 2023-04-13 2024-10-17 Avicenna Biotech Research, Llc Compositions and methods for treating fentanyl dependence

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170728A1 (en) * 2001-11-16 2003-09-11 Randox Laboratories Limited Method and kit for detecting, or determining the quantity of, metabolites of fentanyl and metabolites of fentanyl analogs
JP2008529503A (ja) * 2005-02-08 2008-08-07 ジェンザイム・コーポレイション ＴＧＦβに対する抗体
JP2014502154A (ja) * 2010-11-19 2014-01-30 俊夫 今井 中和抗ｃｃｌ２０抗体
US20140093525A1 (en) * 2012-09-17 2014-04-03 Minneapolis Medical Research Foundation Compositions and methods of treating opioid addiction
JP2015502356A (ja) * 2011-11-30 2015-01-22 ウェルスタット ダイアグノスティクス，エルエルシー ５−ｆｕに関連するアッセイ、抗体、免疫原および組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283066A (en) * 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
CA2132342A1 (en) 1992-04-06 1993-10-14 Kenneth F. Buechler Novel opiate derivatives and protein and polypeptide opiate derivative conjugates and labels
US6262265B1 (en) 1999-06-18 2001-07-17 Microgenics Corporation Non-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay
IN2008CN05409A (enExample) * 2002-07-18 2015-10-02 Cytos Biotechnology Ag
WO2004111202A2 (en) * 2003-03-07 2004-12-23 Incyte Corporation Neurotransmission-association proteins
MXPA04006617A (es) 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.
US20110182918A1 (en) * 2008-06-13 2011-07-28 Nabi Biopharmaceuticals Personalized drug treatment and smoking cessation kit and method
WO2010120121A2 (ko) * 2009-04-15 2010-10-21 포항공과대학교 산학협력단 표적 특이적 비항체 단백질 및 이의 제조 방법
WO2013095321A1 (en) 2011-12-21 2013-06-27 The Scripps Research Institute Heroin haptens, immunoconjugates and related uses
US9981043B2 (en) 2013-02-08 2018-05-29 Regents Of The University Of Minnesota Analgesic conjugates
US9213029B2 (en) * 2013-06-25 2015-12-15 Samsung Electronics Co., Ltd. Method for diagnosing breast cancer by detection of polymeric immunoglobulin receptor in vesicles isolated from patients

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170728A1 (en) * 2001-11-16 2003-09-11 Randox Laboratories Limited Method and kit for detecting, or determining the quantity of, metabolites of fentanyl and metabolites of fentanyl analogs
JP2008529503A (ja) * 2005-02-08 2008-08-07 ジェンザイム・コーポレイション ＴＧＦβに対する抗体
JP2014502154A (ja) * 2010-11-19 2014-01-30 俊夫 今井 中和抗ｃｃｌ２０抗体
JP2015502356A (ja) * 2011-11-30 2015-01-22 ウェルスタット ダイアグノスティクス，エルエルシー ５−ｆｕに関連するアッセイ、抗体、免疫原および組成物
US20140093525A1 (en) * 2012-09-17 2014-04-03 Minneapolis Medical Research Foundation Compositions and methods of treating opioid addiction

Also Published As

Publication number Publication date
CN108884127A (zh) 2018-11-23
RU2018130106A3 (enExample) 2020-05-26
US11305010B2 (en) 2022-04-19
EP3405475A4 (en) 2019-08-28
CA3015336A1 (en) 2017-07-27
RU2018130106A (ru) 2020-02-21
BR112018014908A2 (pt) 2018-12-18
US20210128720A1 (en) 2021-05-06
EP3405475A1 (en) 2018-11-28
WO2017127390A1 (en) 2017-07-27
EP3405475B1 (en) 2022-09-28

Similar Documents

Publication Publication Date Title
JP2019506390A (ja) 合成オピオイドワクチン
Jalah et al. Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers
Stowe et al. A vaccine strategy that induces protective immunity against heroin
Shen et al. A vaccine against methamphetamine attenuates its behavioral effects in mice
EP1024834B1 (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
Moreno et al. Impact of distinct chemical structures for the development of a methamphetamine vaccine
Baruffaldi et al. Preclinical efficacy and characterization of candidate vaccines for treatment of opioid use disorders using clinically viable carrier proteins
Robinson et al. Therapeutic and prophylactic vaccines to counteract fentanyl use disorders and toxicity
Raleigh et al. Opioid dose-and route-dependent efficacy of oxycodone and heroin vaccines in rats
Barrientos et al. Novel vaccine that blunts fentanyl effects and sequesters ultrapotent fentanyl analogues
Collins et al. Investigating hapten clustering as a strategy to enhance vaccines against drugs of abuse
Collins et al. Methamphetamine vaccines: improvement through hapten design
St. John et al. Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy
Taylor et al. Hapten-specific naive B cells are biomarkers of vaccine efficacy against drugs of abuse
CN103323592B (zh) 高通量毒品毒物快速检测芯片及系统
Stevens et al. Optimization of a methamphetamine conjugate vaccine for antibody production in mice
Park et al. Improvements on a chemically contiguous hapten for a vaccine to address fentanyl-contaminated heroin
Zeigler et al. Optimization of a multivalent peptide vaccine for nicotine addiction
AU2017213534B2 (en) Heroin haptens, immunoconjugates and related uses
Lee et al. A vaccine against benzimidazole-derived new psychoactive substances that are more potent than fentanyl
US20190240306A1 (en) Anti-opioid vaccines
Zheng et al. Family of structurally related bioconjugates yields antibodies with differential selectivity against ketamine and 6-hydroxynorketamine
CA3015336C (en) Synthetic opioid vaccine
Park et al. Development of a vaccine against the synthetic opioid U-47700
CN102002049A (zh) 一种抗原及其制备方法与应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210914